Droplet digital PCR and immunohistochemistry analysis of a cohort of ≥65-year-old naïve DLBCL patients revealed that EBF1, MYO6 and CALR expression levels stratify patients for the response to the standard R-CHOP therapy, regardless the IPI score, currently used in clinical settings. Here, CALR is linked to diffuse large B-cell lymphoma.